LIFECORE BIOMEDICAL, INC. Deferred Tax Liabilities, Gross
LIFECORE BIOMEDICAL, INC. (LFCR) had Deferred Tax Liabilities, Gross of $17.18 million as of 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-16
- 2025-12-31: Deferred Tax Liabilities, Gross $17.18M.
- 2025-05-25: Deferred Tax Liabilities, Gross $19.18M.
- 2024-05-26: Deferred Tax Liabilities, Gross $21.18M; Deferred Tax Liabilities, Gross as first filed $20.29M.
- 2023-05-28: Deferred Tax Liabilities, Gross $14.23M; Deferred Tax Liabilities, Gross as first filed $12.43M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $17.18M 10-KT · filed 2026-03-16 | |
| 2025-05-25 | $19.18M 10-KT · filed 2026-03-16 | |
| 2024-05-26 | $21.18M 10-KT · filed 2026-03-16 | $20.29M 10-K · filed 2024-08-26 |
| 2023-05-28 | $14.23M 10-K · filed 2024-08-26 | $12.43M 10-K · filed 2024-03-20 |
| 2022-05-29 | $10.67M 10-K · filed 2024-03-20 | $13.60M 10-K · filed 2022-09-14 |
| 2021-05-30 | $36.48M 10-K · filed 2024-03-20 | |
| 2020-05-31 | $41.05M 10-K · filed 2021-07-29 | |
| 2019-05-26 | $32.07M 10-K · filed 2020-08-14 | |
| 2018-05-27 | $23.23M 10-K · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |